From the Faculty of Medicine, the Division of Endocrinology and Diabetes, Department of Pediatrics, and the Division of Plastic Surgery, Department of Surgery, University of British Columbia; and the Division of Endocrinology and Diabetes, Department of Pediatrics, and the Division of Plastic Surgery, Department of Surgery, BC Children's Hospital.
Plast Reconstr Surg. 2018 Jul;142(1):9e-16e. doi: 10.1097/PRS.0000000000004465.
Primary evidence for the role of endocrinologic investigations in patients with adolescent gynecomastia is lacking in the current literature. The objective of this study was to assess the yield of endocrinologic investigations in the evaluation of adolescent gynecomastia to inform current practice for this common condition.
A 26-year retrospective review was conducted. Data collection included patients with gynecomastia presenting to endocrinology at a quaternary children's hospital with a catchment area of 1 million. Clinical metrics, endocrinologic results, treatments, and costs were reviewed.
One hundred ninety-seven patients met inclusion criteria. Ninety-eight (50 percent) were overweight or obese and 29 (15 percent) had a positive family history. The median age at onset was 11.5 years; 25 cases (13 percent) were prepubertal. A total of 15 patients (7.6 percent) were diagnosed with secondary gynecomastia (10 related to exogenous substance use). Endocrine investigations were performed in 173 patients (87 percent), with positive findings in three cases (1.7 percent). One hundred one patients were observed, with a median age at resolution of 14.6 years; 86 patients underwent surgery at a median age of 16.5 years. The case-cost of endocrine evaluation was $389.
Endocrinologic workup identified secondary gynecomastia in 7.6 percent of patients, of which only 1.7 percent were evident on blood work. This workup is associated with an avoidable case-cost burden to the health care system and largely unnecessary testing for the child. Because a majority of secondary gynecomastia cases (67 percent) were drug-induced, we do not suggest routine endocrinology workup, as it adds little value. The authors' data suggest that referral for surgery is warranted if gynecomastia persists beyond 16 years of age.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Diagnostic, IV.
目前的文献中缺乏青少年男性乳房发育症患者内分泌检查作用的主要证据。本研究的目的是评估内分泌检查在评估青少年男性乳房发育症中的效果,为这一常见病症提供当前的实践依据。
进行了一项为期 26 年的回顾性研究。数据收集包括在一家四级儿童医院内分泌科就诊的男性乳房发育症患者,该医院的服务区域有 100 万人。对临床指标、内分泌结果、治疗和费用进行了回顾。
符合纳入标准的患者有 197 人。其中 98 人(50%)超重或肥胖,29 人(15%)有阳性家族史。发病年龄中位数为 11.5 岁,25 例(13%)为青春期前发病。共有 15 例(7.6%)患者被诊断为继发性男性乳房发育症(10 例与外源性物质使用有关)。对 173 例患者(87%)进行了内分泌检查,其中 3 例(1.7%)发现阳性结果。101 例患者接受了观察治疗,其缓解年龄中位数为 14.6 岁;86 例患者在 16.5 岁的年龄中位数时接受了手术治疗。内分泌评估的病例成本为 389 美元。
内分泌检查发现 7.6%的患者存在继发性男性乳房发育症,其中只有 1.7%的患者血液检查结果异常。这种检查与医疗保健系统的可避免的病例成本负担以及对儿童的大量不必要的检查有关。由于大多数继发性男性乳房发育症病例(67%)是药物引起的,因此我们不建议常规进行内分泌检查,因为这几乎没有增加价值。作者的数据表明,如果男性乳房发育症持续超过 16 岁,应考虑进行手术转诊。
临床问题/证据水平:诊断,IV。